Seattle Genetics Receives U.S. Patent Relating to Its Antibody-Drug Conjugate Technology.BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN SGEN Signal/System Generator ) announced today that it has received a patent issued by the U.S. Patent and Trademark Office (USPTO USPTO abbr. United States Patent and Trademark Office ) relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the company's antibody-drug conjugate conjugate /con·ju·gate/ (kon´jdbobr-gat) 1. paired, or equally coupled; working in unison. 2. a conjugate diameter of the pelvic inlet; used alone usually to denote the true conjugate diameter; see (ADC (1) See A/D converter. (2) (Apple Display Connector) A peripheral connector from Apple that combines digital video display, USB and power in one cable. ) technology. U.S. Patent No. 6,884,869 covers the drug compound monomethyl auristatin E (MMAE MMAE Multiple Model Adaptive Estimation (Bayesian technique using Kalman filters) MMAE Mechanical, Materials and Aerospace Engineering MMAE Multiple Model Adaptive Estimator MMAE Monomethyl Auristatin E ) and its variants, which Seattle Genetics utilizes with its proprietary linker technology to develop ADCs. By linking potent, cytotoxic drug cytotoxic drug Oncology An anticancer drug which acts by killing or preventing the cell division Adverse effects Damage to noncancerous tissues or organs with a high proportion of actively dividing cells–eg, BM, hair follicles, GI tract, thereby limiting the payloads to monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). , ADCs can increase the therapeutic potential of antibodies that have inherent cell targeting ability. "This patent provides additional intellectual property protection for several novel drugs we utilize in our second-generation ADC technology, and is an important addition to our patent portfolio," stated Eric L. Dobmeier, Senior Vice President, Corporate Development and General Counsel of Seattle Genetics. "We employ our ADC technology to empower antibody-based products in our own pipeline, including SGN-35 and SGN-75, as well as partner this technology with leading biotechnology and pharmaceutical companies including Genentech, Bayer, CuraGen and, most recently, MedImmune." Seattle Genetics' second-generation ADC technology utilizes the targeting ability of monoclonal antibodies to deliver potent, cell-killing payloads to specific cells. This ADC technology employs synthetic, highly potent drugs, such as MMAE, that can be attached to antibodies through proprietary linker systems. The linkers are designed to be stable in the bloodstream but to release the drug payload (1) Refers to the "actual data" in a packet or file minus all headers attached for transport and minus all descriptive meta-data. In a network packet, headers are appended to the payload for transport and then discarded at their destination. under specific conditions once inside target cells, potentially sparing non-target cells many of the toxic effects of traditional chemotherapy. About Seattle Genetics Seattle Genetics is a biotechnology company focused on the development of monoclonal antibody-based therapies for the treatment of cancer and immunologic diseases. The company is conducting clinical and preclinical development of a diverse portfolio of product candidates in a variety of oncology and immunology settings. In addition, Seattle Genetics has developed proprietary antibody-drug conjugate (ADC) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. The company currently has license agreements for its ADC technology with Genentech, UCB UCB - University of California at Berkeley Celltech, Protein Design Labs, CuraGen, Bayer and MedImmune. More information about Seattle Genetics' pipeline and technologies can be found at www.seattlegenetics.com. Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the therapeutic potential of ADCs and the strength of Seattle Genetics' intellectual property portfolio. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks related to adverse clinical results as our product candidates move into and advance in clinical trials, risks inherent in early stage development and failure by Seattle Genetics to secure or maintain relationships with collaborators. More information about the risks and uncertainties faced by Seattle Genetics is contained in the Company's filings with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion